Skip to main content

Table 3 Adverse events

From: Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study

Adverse event

Grade I/II (%)

Grade III/IV (%)

TKIs (n = 90)

TKIs + SBRT (n = 45)

p

TKIs (n = 90)

TKIs + SBRT (n = 45)

p

Rash

37 (41.1%)

20 (44.4%)

0.712

8 (8.9%)

3 (6.7%)

0.656

Diarrhea

26 (28.9%)

14 (31.1%)

0.790

0 (0.0%)

0 (0.0%)

 

Dry skin

26 (28.9%)

11 (24.4%)

0.585

0 (0.0%)

0 (0.0%)

 

Paronychia

17 (18.9%)

8 (17.8%)

0.876

2 (2.2%)

0 (0.0%)

0.552

Mucositis

19 (21.1%)

9 (20.0%)

0.881

0 (0.0%)

0 (0.0%)

 

Anorexia

13 (14.4%)

6 (13.3%)

0.861

0 (0.0%)

0 (0.0%)

 

Elevated aminotransferase

23 (25.6%)

14 (31.1%)

0.495

6 (6.7%)

4 (8.9%)

0.642

Nausea or vomiting

8 (8.9%)

6 (13.3%)

0.425

0 (0.0%)

0 (0.0%)

 

Interstitial pneumonia

3 (3.3%)

1 (2.2%)

0.858

0 (0.0%)

0 (0.0%)

 

Radiation pneumonitis

0 (0.0%)

15 (33.3%)

< 0.001

0 (0.0%)

2 (4.4%)

0.109

Radiation esophagitis

0 (0.0%)

3 (6.7%)

0.035

0 (0.0%)

0 (0.0%)

 

Fatigue

7 (7.8%)

14 (31.1%)

< 0.001

0 (0.0%)

0 (0.0%)

 

Radiation dermatitis

0 (0.0%)

5 (11.1%)

0.004

0 (0.0%)

0 (0.0%)

 
  1. SBRT stereotactic body radiation therapy, TKIs tyrosine kinase inhibitors